Pere Sanatamaria

Navacims Are Breakthrough Science For Autoimmune Disease


Navacims Are Nanoparticles Coated With Immune System Proteins To Fight Disease

Tailored Navacims

Navacims Can Be Tailored To Different Diseases Including T1D, Multiple Sclerosis & Arthritis


Parvus is pioneering a breakthrough class of disease-specific biological therapeutics called NavacimsTM that are designed to halt and potentially cure autoimmune disease by restoring immune tolerance. The Company’s robust therapeutic platform is capable of generating a rich pipeline of therapeutic candidates for a wide range of autoimmune diseases. Parvus has validated two lead drug candidates to take into clinical development for Type 1 diabetes (T1D) and Multiple Sclerosis (MS), and is scaling up drug product manufacture for GLP toxicology studies.

Parvus Press Release 04-19-2017: Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes